Monopar Therapeutics Files 8-K Report
Ticker: MNPR · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Monopar filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On April 16, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Monopar Therapeutics is providing updated financial information or exhibits to the SEC, which could be relevant for investors assessing the company's current financial standing.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material non-public information that would immediately alter risk assessment.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- April 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Address of principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The filing is a Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, primarily indicating 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The date of the earliest event reported is April 16, 2024.
In which state is Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Monopar Therapeutics?
The address of the principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics' securities?
The provided excerpt lists 'Trading Symbol(s)' but does not specify the symbol for Monopar Therapeutics.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-04-16 08:00:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240415_8k.htm (8-K) — 25KB
- ex_654179.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-012131.txt ( ) — 180KB
- mnpr-20240416.xsd (EX-101.SCH) — 3KB
- mnpr-20240416_def.xml (EX-101.DEF) — 12KB
- mnpr-20240416_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240416_pre.xml (EX-101.PRE) — 12KB
- mnpr20240415_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 16, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated April 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: April 16, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director